SHENZHEN, China, Nov. 25, 2015 /PRNewswire/ -- China Nepstar
Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"),
a leading retail drugstore chain in China based on the number of directly operated
stores, today announced its unaudited financial results for the
third quarter ended September 30, 2015.
Financial Highlights
For the quarter ended September 30, 2015:
- Same store sales increased by 13.2% compared to the third
quarter of 2014
- Revenue increased by 7.4% to RMB793.0 million (US$124.8 million) compared to the third quarter
of 2014
- Gross margin was 40.9%
- Opened 47 stores while closed 30 stores in the third quarter of
2015, with 1,965 stores as of September 30,
2015
- Net loss was RMB2.8
million (US$0.4 million)
Ms. Rebecca Zhang, Chief
Executive Officer of Nepstar, commented, "Our dedicated efforts on
growing store productivity propelled the increase in revenue and
same store sales. We continued to optimize the marketing programs
and product mix to drive the improvement in gross margin. We will
further optimize our management structure to achieve the
organizational efficiency from head office to stores."
Third Quarter Results
During the third quarter of 2015, the Company opened 47 new
stores while it closed 30 stores. As of September 30, 2015,
the Company had 1,965 directly operated stores in total.
Revenue for the third quarter of 2015 increased by 7.4%
to RMB793.0 million (US$124.8
million) from RMB738.3 million for the same period
in 2014. Same store sales (for the 1,740 stores opened
before December 31, 2013 and which were still operating as of
September 30, 2015) for the third
quarter of 2015 increased by 13.2% compared to the same period in
2014. The increase in same store sales was primarily due to
in-store marketing initiatives and improved product mix.
Third quarter revenue contribution by product category was 23.4%
from prescription drugs (22.7% for the same period in 2014), 43.1%
from over-the-counter ("OTC") drugs (38.7% for the same period in
2014), 17.6% from convenience and other products (21.0% for the
same period in 2014), 11.5% from nutritional supplements (13.6% for
the same period in 2014), and 4.4% from herbal products (4.0% for
the same period in 2014).
Third quarter gross profit was RMB324.0
million (US$51.0 million)
compared to RMB298.3 million in
the same period of 2014. Gross margin in the third quarter of 2015
was 40.9%, compared with 40.4% in the same period of 2014. The
year-over-year increase in gross margin was mainly the result of
improved product mix and increased store productivity.
The Company's portfolio of private label products expanded to
2,165 types of products as of September 30, 2015. Sales of
private label products represented approximately 13.6% of the
Company's revenue and 20.5% of the gross profit for the third
quarter of 2015.
Sales, marketing and other operating expenses as a percentage of
revenue decreased slightly to 37.0% for the third quarter of 2015
from 37.9% in the same period of 2014.
General and administrative expenses as a percentage of revenue
were 3.3% for the third quarter of 2015 compared to 4.1% for the
same period of 2014. This was mainly due to the Company's efforts
to improve efficiencies and the write-off of certain accounts
payables when the de-recognition threshold was met.
Income from operations in the third quarter of 2015 was
RMB4.5 million (US$0.7 million) compared with loss from
operations of RMB13.1 million in
the same period of 2014. This increase was mainly due to the
continuous revenue growth and improved margin.
Interest and investment income for the third quarter of 2015
was RMB1.1 million (US$0.2
million), compared with RMB1.5 million in the same
period of 2014.
The Company's income tax expense was RMB8.4 million. The difference in the effective
income tax rate and the PRC statutory tax rate of 25% applicable to
our major operating subsidiaries was primarily due to
non-deductible expenses and the operating losses from certain
loss-making subsidiaries, for which full valuation allowances were
made on their deferred tax assets, when compared to the overall
results of operation of the Company. Shareholders are reminded that
in the PRC, losses in companies which are part of a group are not
allowed to be off-set against profits arising from other companies
in the same group.
Net loss for the third quarter of 2015 was RMB2.8
million (US$0.4 million), or
RMB0.03 (US$0.004) per basic and diluted ADS compared to
net loss of RMB 13.1 million, or
RMB0.13 basic and diluted losses per
ADS for the third quarter of 2014. As of September 30, 2015, the Company had 197.4 million
outstanding ordinary shares. Each ADS represents two ordinary
shares of the Company.
In the third quarter of 2015, net cash inflow from operating
activities were RMB27.4 million (US$4.3 million), compared to net cash outflow of
RMB1.2 million for the same period in
2014.
As of September 30, 2015, the Company's total cash, cash
equivalents, short-term and long-term bank deposits and restricted
cash were RMB346.0 million (US$54.4
million) and its shareholders' equity was RMB834.1
million (US$131.2 million),
compared with total cash, cash equivalents, bank deposits and
restricted cash of RMB316.9 million and shareholders' equity
of RMB831.6 million as of
December 31, 2014.
Business Outlook
"Product mix and store staff will be our two key focuses next.
We will strive to improve store image to increase the loyalty with
our customers. While keeping the goal of maintaining gross margin,
we will continue to optimize product mix and omni-channel marketing
campaigns. We are confident that, with continued improvements in
performance of each store, we will maintain our growth
momentum," Ms. Zhang concluded.
Conference Call Information
The Company will host a conference call, to be simultaneously
webcasted, on Wednesday, November 25,
2015 at 8:00 a.m. Eastern Standard
Time / 9:00 p.m. Beijing Time.
Interested parties may participate in the conference call by
dialing +1-877-407-9210 (North
America) or +1-201-689-8049 (International) approximately
five minutes before the call start time. A live web cast of the
conference call will be available on the Nepstar website at
www.nepstar.cn.
A replay of the call will be available shortly after the
conclusion of the conference call through December 1, 2015 at 11:59
p.m. Eastern Standard Time. An archived web cast of the
conference call will be available on the Nepstar website at
http://www.nepstar.cn. Interested parties may access the replay by
dialing +1-877-660-6853 (North
America) or +1-201-612-7415 (International) and entering
conference ID number 13623845.
About China Nepstar Chain Drugstore
Ltd.
China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is a
leading retail drugstore chain in China. As
of September 30, 2015, the Company had 1,965 directly operated
stores across 71 cities, one headquarter distribution center and 14
regional distribution centers in China. Nepstar uses directly
operated stores, centralized procurement and a network of
distribution centers to provide its customers with high-quality,
professional and convenient pharmaceutical products and services
and a wide variety of other merchandise, including OTC drugs,
nutritional supplements, herbal products, personal care products,
family care products, and convenience products. Nepstar's strategy
of centralized procurement, competitive pricing, customer loyalty
programs and private label offerings has enabled it to capitalize
on the continuing economic growth in China and take
advantage of the demographic trend in China to achieve a
strong brand and leading market position. For further information,
please go to http://www.nepstar.cn.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute "forward-looking" statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar
statements. Among other things, the quotations from management in
this press release and the Company's strategic operational plans
and business outlook, contain forward-looking statements. Such
statements involve certain risks and uncertainties that could cause
actual results to differ materially from those in the
forward-looking statements. Further information regarding these and
other risks is included in the Company's filings with the U.S.
Securities and Exchange Commission, including its annual report on
Form 20-F. The Company does not undertake any obligation to update
any forward-looking statement as a result of new information,
future events or otherwise, except as required under applicable
law.
Exchange Rate Information
The United States dollar (US$) amounts disclosed in this
press release are presented solely for the convenience of the
reader. Translations of amounts from RMB into United
States dollars were calculated at the certified exchange rate
of US$1.00 = RMB6.3556
on September 30, 2015 as set forth in the H.10 weekly
statistical release of the Federal Reserve Board. No representation
is made that the RMB amounts could have been, or could be,
converted into US$ at that rate on September 30, 2015, or at
any other date. The percentages stated are calculated based on RMB
amounts.
Contacts
Zixin Shao
China Nepstar Chain Drugstore Ltd.
Chief Financial Officer
+86-755-2641-4065
ir@nepstar.cn
(Tables Follow)
China Nepstar
Chain Drugstore Ltd.
|
Unaudited Condensed
Consolidated Statements of Comprehensive Loss
|
(amounts in
thousands -- except per-share and per-ADS data)
|
|
|
|
Three-month period
ended
|
September
30,
|
|
2014
|
2015
|
2015
|
|
RMB
|
RMB
|
USD
|
|
|
|
|
Revenue
|
738,334
|
792,995
|
124,771
|
Cost of goods
sold
|
(440,022)
|
(468,986)
|
(73,791)
|
Gross
profit
|
298,312
|
324,009
|
50,980
|
Sales, marketing and
other operating expenses
|
(279,496)
|
(293,077)
|
(46,113)
|
General and
administrative expenses
|
(30,173)
|
(26,462)
|
(4,164)
|
Impairment losses of
property and equipment
|
(1,740)
|
-
|
-
|
(Loss)/income from
operations
|
(13,097)
|
4,470
|
703
|
Interest and
investment income
|
1,487
|
1,096
|
173
|
Other
income
|
2,956
|
117
|
18
|
(Loss)/income before
income tax expense
|
(8,654)
|
5,683
|
894
|
Income tax
expense
|
(4,467)
|
(8,439)
|
(1,328)
|
Net loss
|
(13,121)
|
(2,756)
|
(434)
|
|
|
|
|
Basic and diluted
loss per ordinary share
|
(0.066)
|
(0.014)
|
(0.002)
|
Basic and diluted
loss per ADS
|
(0.132)
|
(0.028)
|
(0.004)
|
|
|
|
|
Net loss
|
(13,121)
|
(2,756)
|
(434)
|
|
|
|
|
Other comprehensive
loss, net of tax:
|
|
|
|
Foreign currency
translation adjustments
|
(10)
|
(52)
|
(8)
|
Comprehensive
loss
|
(13,131)
|
(2,808)
|
(442)
|
China Nepstar
Chain Drugstore Ltd.
|
Unaudited Condensed
Consolidated Balance Sheets
|
(amounts in
thousands)
|
|
|
As
of
|
|
As
of
|
|
As
of
|
December
31,
|
|
September
30,
|
|
September
30,
|
|
2014
|
|
2015
|
|
2015
|
|
RMB
|
|
RMB
|
|
USD
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
Cash and cash
equivalents
|
252,174
|
|
336,849
|
|
53,000
|
Short-term bank time
deposits
|
24,000
|
|
9,000
|
|
1,416
|
Long-term bank time
deposits due within one year
|
3,256
|
|
-
|
|
-
|
Restricted
cash
|
37,423
|
|
124
|
|
20
|
Accounts receivable,
net of allowance for doubtful
accounts
|
136,568
|
|
145,080
|
|
22,827
|
Bills
receivable
|
400
|
|
-
|
|
-
|
Amounts due from
related parties
|
3,366
|
|
4,216
|
|
663
|
Prepaid expenses,
deposits and other current assets
|
245,254
|
|
165,448
|
|
26,032
|
Inventories
|
546,312
|
|
593,959
|
|
93,454
|
Deferred tax
assets
|
2,038
|
|
4,885
|
|
769
|
Total current
assets
|
1,250,791
|
|
1,259,561
|
|
198,181
|
|
|
|
|
|
|
Non-current
assets
|
|
|
|
|
|
Property and
equipment, net
|
137,750
|
|
166,415
|
|
26,184
|
Rental
deposits
|
42,257
|
|
43,884
|
|
6,905
|
Cost method
investments
|
12,638
|
|
12,493
|
|
1,966
|
Intangible assets,
net
|
2,509
|
|
2,509
|
|
395
|
Goodwill
|
51,819
|
|
51,819
|
|
8,153
|
Deferred tax
assets
|
16,340
|
|
11,372
|
|
1,789
|
Other non-current
assets
|
-
|
|
37,443
|
|
5,891
|
Total non-current
assets
|
263,313
|
|
325,935
|
|
51,283
|
Total
assets
|
1,514,104
|
|
1,585,496
|
|
249,464
|
|
|
|
|
|
|
LIABILITIES AND
SHAREHOLDERS'
EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
Accounts
payable
|
409,428
|
|
476,941
|
|
75,043
|
Amounts due to
related parties
|
25,636
|
|
22,811
|
|
3,589
|
Accrued expenses and
other payables
|
122,236
|
|
122,400
|
|
19,258
|
Income tax
payable
|
25,743
|
|
23,860
|
|
3,754
|
Deferred
income
|
25,715
|
|
37,395
|
|
5,884
|
Total current
liabilities
|
608,758
|
|
683,407
|
|
107,528
|
|
|
|
|
|
|
Non-current
liabilities
|
|
|
|
|
|
Deferred
income
|
15,677
|
|
12,908
|
|
2,031
|
Deferred tax
liabilities
|
14,711
|
|
15,091
|
|
2,374
|
Other non-current
liabilities
|
43,326
|
|
39,949
|
|
6,286
|
Total non-current
liabilities
|
73,714
|
|
67,948
|
|
10,691
|
Total
liabilities
|
682,472
|
|
751,355
|
|
118,219
|
|
|
|
|
|
|
Shareholders'
equity
|
|
|
|
|
|
Share
capital
|
158
|
|
158
|
|
25
|
Additional paid-in
capital
|
640,341
|
|
640,341
|
|
100,752
|
Accumulated other
comprehensive loss
|
(41,746)
|
|
(41,805)
|
|
(6,578)
|
Retained
earnings
|
232,879
|
|
235,447
|
|
37,046
|
Total shareholders'
equity
|
831,632
|
|
834,141
|
|
131,245
|
|
|
|
|
|
|
Total liabilities
and shareholders' equity
|
1,514,104
|
|
1,585,496
|
|
249,464
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/china-nepstar-chain-drugstore-ltd-reports-third-quarter-2015-financial-results-300184406.html
SOURCE China Nepstar Chain Drugstore Ltd.